Tevogen Reaffirms $1 Billion Launch-Year Oncology Revenue And $10–14 Billion Five-Year Outlook

Tevogen Bio Holdings Inc. has reaffirmed its top-line revenue guidance for its oncology pipeline, projecting $1 billion in first-year sales and a cumulative $10–14 billion over five years. The forecast builds on the company’s rapid and cost-efficient development strategy. This revenue outlook underscores Tevogen’s innovative model, which aims to accelerate drug development timelines and reduce capital barriers compared to traditional biopharma approaches. 

“With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,” commented Ryan Saadi, MD, MPH, founder and CEO of Tevogen.